Outset Medical (OM) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T16:52:39.788Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:52:39.788Z.

Quote observation: 2026-10-06T16:49:32.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 4.11
Unrounded diluted TTM EPS · period ending 2026-06-30: -4.09

FMP input reference: e005637c0728ee7719d987fd9d1ed1bb4b4a72c9577e4c0c1fad472fb0ddb1d0

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

OM PE Ratio Metrics

PE RATIO

N/A

OM Competitors' PE Ratio

OM

Outset Medical, Inc.

Current

Market Cap

$76.19M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SKIN

SkinHealth Systems Inc.

vs OM

Market Cap

$76.44M

PE Ratio

N/A

TTM Avg

63.47

3Y Avg

35.79

5Y Avg

35.79

HYPR

Hyperfine, Inc.

vs OM

Market Cap

$76.65M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SERA

Sera Prognostics, Inc.

vs OM

Market Cap

$77.15M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NTHI

Neonc Technologies Holdings, Inc.

vs OM

Market Cap

$77.80M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUNG

Pulmonx Corporation

vs OM

Market Cap

$78.40M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INO

Inovio Pharmaceuticals, Inc.

vs OM

Market Cap

$79.36M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GANX

Gain Therapeutics, Inc.

vs OM

Market Cap

$72.30M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTOR

Citius Oncology, Inc.

vs OM

Market Cap

$80.19M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NTRB

Nutriband Inc.

vs OM

Market Cap

$80.32M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Outset Medical, Inc. (OM)	$76.19M	N/A	N/A	N/A	N/A
SkinHealth Systems Inc. (SKIN)vs ›	$76.44M	N/A	63.47	35.79	35.79
Hyperfine, Inc. (HYPR)vs ›	$76.65M	N/A	N/A	N/A	N/A
Sera Prognostics, Inc. (SERA)vs ›	$77.15M	N/A	N/A	N/A	N/A
Neonc Technologies Holdings, Inc. (NTHI)vs ›	$77.80M	N/A	N/A	N/A	N/A
Pulmonx Corporation (LUNG)vs ›	$78.40M	N/A	N/A	N/A	N/A
Inovio Pharmaceuticals, Inc. (INO)vs ›	$79.36M	N/A	N/A	N/A	N/A
Gain Therapeutics, Inc. (GANX)vs ›	$72.30M	N/A	N/A	N/A	N/A
Citius Oncology, Inc. (CTOR)vs ›	$80.19M	N/A	N/A	N/A	N/A
Nutriband Inc. (NTRB)vs ›	$80.32M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$4.11

÷

Forward EPS (Est.)

$-3.08

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

OM PE Ratio Metrics

OM Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics